Recent Advances in D-Allulose Physiological Functions and Biosynthesis

Why this review matters

D-allulose is easy to dismiss as just another rare sugar. This review says otherwise. Published in Frontiers in Microbiology (DOI: 10.3389/fmicb.2022.881037), it pulls together current evidence on both the physiological side and the production side. For food formulators and ingredient buyers, that combination is useful. One side tells you why consumers might want it. The other tells you whether supply can keep up.

Background: more than a sweetener

D-allulose, or D-psicose, is an epimer of fructose. It occurs naturally in small quantities. It tastes like sugar but delivers minimal calories. Most formulators first encounter allulose as a bulking sweetener. That’s a fair entry point. But the review positions allulose as a bioactive ingredient, not just a sugar swap.

The authors describe several physiological functions. These include anti-obesity effects, blood sugar control, anti-diabetic activity, anti-inflammatory properties, antioxidant action, and neuroprotective potential. That is a wide range. Some evidence is stronger than others. Still, the pattern is consistent: allulose does something beyond sweetness.

What the study did

The authors did not run a new clinical trial. They reviewed recent literature and organized it into two big buckets. The first bucket covers physiological functions. The second covers biosynthesis strategies for producing allulose more efficiently.

Both buckets matter. A functional ingredient only works if you can make it affordable at scale. So the review spends real time on production methods. It highlights the Izumoring strategy and the DHAP-dependent aldolase strategy. These are enzyme-based routes to allulose. They matter because they can lower cost and improve yield compared with older approaches.

Key findings

The review makes a clear case that allulose is more than a low-calorie sugar. One clinical data point stands out. In normal adults, adding just 5 grams of D-allulose significantly suppressed the blood sugar rise caused by 75 grams of maltodextrin. That’s a small dose. It’s a practical dose. You can fit 5 grams into many product formats.

The table below summarizes the physiological effects the review covers.

Reported physiological effect	Relevance for formulators
Anti-obesity	Potential fit for weight management products
Hypoglycemic / anti-diabetic	Possible support for lower-glycemic claims
Anti-inflammatory	Interest for functional beverages and recovery
Antioxidant	Appeal for daily wellness and active nutrition
Neuroprotective	Early-stage, but interesting for cognitive positioning

Read that table with care. The review reports what researchers have observed. It does not guarantee a regulatory claim. But it gives R&D teams a starting point.

What this means for manufacturers

Use this review as a roadmap, not a label claim. It tells you where allulose might add value. It does not give you permission to put health claims on your packaging.

The 5-gram data point is the most actionable piece of evidence here. A formulator developing a bar, beverage, or powdered drink can test a serving with 5 grams of allulose. The product still needs to taste good. It still needs to handle well in processing. But the glycemic response data gives you a reason to invest in that development work.

The biosynthesis content matters just as much on the commercial side. Efficient enzymatic production means more stable supply and better pricing. If you buy allulose in bulk, you should watch which production strategy your supplier uses. The review’s focus on Izumoring and aldolase strategies suggests the industry is moving beyond early-stage extraction methods.

FAQ

Does the 5-gram blood sugar effect apply to everyone?
The review cites data from normal adults. That doesn’t mean every population or product matrix will behave the same. Run your own sensory and clinical validation for your specific application.

Is D-allulose just a rare sugar?
It functions as a rare sugar in sweetness and texture. But this review positions it as a bioactive ingredient with multiple physiological effects. That makes it a more interesting tool for product differentiation.

Which biosynthesis method should suppliers use?
The review describes the Izumoring strategy and the DHAP-dependent aldolase strategy. Both have strengths depending on starting materials and yield goals. Buyers should compare suppliers on cost, scalability, and consistency rather than choosing a method in the abstract.

Closing thoughts

This review gives formulators a reason to look at D-allulose beyond sweetness. The physiological data is still evolving. The biosynthesis data suggests more efficient production is coming. Both trends point in the same direction. D-allulose is moving from specialty ingredient to mainstream option. That shift starts with research like this.